Remix Therapeutics has filed a notice of an exempt offering of securities to raise $90,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Remix Therapeutics is raising $90,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Peter Smith played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Remix Therapeutics
Remix launched in 2020 with a vision to transform patients lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
To learn more about Remix Therapeutics, visit http://www.remixtx.com/
Contact:
Peter Smith, President and Chief Executive Officer
781-827-0901
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.